GlassScriptPhysician profile
Robin Laberge
NPI 1033542717
$5,849.09
in general payments reported to CMS, 2019-2025
27 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $694 · 2022: $1,466 · 2023: $965 · 2024: $1,146 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.30 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $737.39 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $649.85 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $485.70 | 2021-2025 | |
| Gilead Sciences, INC. | $367.93 | 2021-2025 | |
| Janssen Biotech, INC. | $367.91 | 2022-2025 | Tremfya, Stelara |
| Genzyme Corporation | $284.50 | 2022-2025 | |
| Lilly USA, LLC | $275.78 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $232.42 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $159.52 | 2021-2024 | |
| Celgene Corporation | $127.21 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $116.85 | 2021-2025 | Sucraid |
| Neuraxis, INC. | $87.50 | 2025 | |
| Celltrion USA INC. | $78.51 | 2024-2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $62.51 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $51.88 | 2021-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $36.12 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $35.86 | 2024-2025 | Ibsrela |
| Currax Pharmaceuticals LLC | $32.91 | 2025 | Contrave |
| Ipsen Biopharmaceuticals, INC | $30.87 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $30.47 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $24.47 | 2025 | Zenpep |
| Shield Therapeutics INC | $19.72 | 2023 | Accrufer |
| Alfasigma USA, INC. | $17.49 | 2022 | |
| Braintree Laboratories, INC. | $15.17 | 2025 | Sutab |
| Novo Nordisk INC | $14.12 | 2025 | Wegovy |
| Medtronic, INC. | $13.13 | 2024 | Signia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Laberge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.